Physician profile
Rick C Chatwell
NPI 1841260478
$2,040.80
in general payments reported to CMS, 2019-2025
21 companies · $52.88 in 2025
The $52.88 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $42.38 · 2021: $248 · 2022: $516 · 2023: $458 · 2024: $447 · 2025: $52.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $609.34 | 2019-2025 | Amjevita, Prolia, Evenity |
| Glaxosmithkline, LLC. | $218.89 | 2019-2024 | Benlysta |
| Abbvie INC. | $205.06 | 2019-2024 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $176.35 | 2019-2023 | |
| Janssen Biotech, INC. | $173.52 | 2019-2024 | Tremfya |
| Pfizer INC. | $154.13 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $92.66 | 2021-2024 | |
| Aurinia Pharma U.S., INC. | $81.74 | 2021-2023 | Lupkynis |
| Ucb, INC. | $73.36 | 2019-2024 | Cimzia, Bimzelx |
| Genentech USA, INC. | $58.52 | 2019-2024 | Actemra |
| Lilly USA, LLC | $35.72 | 2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $29.76 | 2022 | |
| Organon LLC | $19.23 | 2024 | |
| Sandoz INC. | $18.26 | 2023 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $18.06 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.29 | 2024 | Hyqvia |
| Kiniksa Pharmaceuticals International, Plc | $13.59 | 2024 | Arcalyst |
| Janssen Scientific Affairs, LLC | $13.48 | 2019 | |
| Celgene Corporation | $13.21 | 2019 | |
| Horizon Therapeutics Plc | $11.67 | 2022 | |
| Fidia Pharma USA INC. | $9.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rick Chatwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.